Free Trial
NASDAQ:AMRN

Amarin (AMRN) Stock Price, News & Analysis

Amarin logo
$0.46 +0.01 (+2.95%)
(As of 12/24/2024 05:19 PM ET)

About Amarin Stock (NASDAQ:AMRN)

Key Stats

Today's Range
$0.44
$0.46
50-Day Range
$0.44
$0.63
52-Week Range
$0.43
$1.37
Volume
1.26 million shs
Average Volume
1.55 million shs
Market Capitalization
$187.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Buy

Company Overview

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Amarin Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
5th Percentile Overall Score

AMRN MarketRank™: 

Amarin scored higher than 5% of companies evaluated by MarketBeat, and ranked 944th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Amarin are expected to decrease in the coming year, from ($0.14) to ($0.24) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Amarin is -5.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Amarin is -5.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Amarin has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.37% of the outstanding shares of Amarin have been sold short.
  • Short Interest Ratio / Days to Cover

    Amarin has a short interest ratio ("days to cover") of 16.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Amarin has recently increased by 0.11%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Amarin does not currently pay a dividend.

  • Dividend Growth

    Amarin does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.37% of the outstanding shares of Amarin have been sold short.
  • Short Interest Ratio / Days to Cover

    Amarin has a short interest ratio ("days to cover") of 16.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Amarin has recently increased by 0.11%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Amarin has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Amarin this week, compared to 2 articles on an average week.
  • Search Interest

    4 people have searched for AMRN on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added Amarin to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Amarin insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.96% of the stock of Amarin is held by insiders.

  • Percentage Held by Institutions

    Only 22.25% of the stock of Amarin is held by institutions.

  • Read more about Amarin's insider trading history.
Receive AMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter.

AMRN Stock News Headlines

Amarin (NASDAQ:AMRN) Earns Hold Rating from Analysts at StockNews.com
70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!
Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.
Amarin Names Peter Fishman Finance Chief
Amarin Appoints Peter Fishman Chief Financial Officer
See More Headlines

AMRN Stock Analysis - Frequently Asked Questions

Amarin's stock was trading at $0.87 on January 1st, 2024. Since then, AMRN shares have decreased by 47.5% and is now trading at $0.4567.
View the best growth stocks for 2024 here
.

Amarin Co. plc (NASDAQ:AMRN) released its quarterly earnings results on Wednesday, October, 30th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.02. The biopharmaceutical company earned $42.30 million during the quarter, compared to analyst estimates of $43.82 million. Amarin had a negative trailing twelve-month return on equity of 7.22% and a negative net margin of 16.33%.

Amarin subsidiaries include these companies: Ester Neurosciences, Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharmaceuticals Ireland Limited, Amarin Pharma Inc., Amarin Switzerland GmbH, Amarin UK Limited, and Ester Neurosciences Limited.

Amarin's top institutional shareholders include Longitude Cayman Ltd. (0.58%), BNP Paribas Financial Markets (0.32%), Cutter & CO Brokerage Inc. (0.07%) and Kornitzer Capital Management Inc. KS (0.02%). Insiders that own company stock include Aaron Berg, Steven B Ketchum, Patrick Holt and Olsen Per Wold.
View institutional ownership trends
.

Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Amarin investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT ().

Company Calendar

Last Earnings
10/30/2024
Today
12/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AMRN
Fax
N/A
Employees
360
Year Founded
1991

Profitability

Net Income
$-59,110,000.00
Pretax Margin
-12.34%

Debt

Sales & Book Value

Annual Sales
$241.02 million
Book Value
$1.35 per share

Miscellaneous

Free Float
402,623,000
Market Cap
$187.55 million
Optionable
Optionable
Beta
1.83

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

This page (NASDAQ:AMRN) was last updated on 12/25/2024 by MarketBeat.com Staff
From Our Partners